Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will examine the effectiveness of pegylated interferon, or peginterferon (a
long-acting form of alpha interferon) plus ribavirin in treating hepatitis C (genotype 1)
infection with and without kidney disease.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)